Parmax Pharma Ltd vs Rekvina Labs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Parmax Pharma Ltd is ₹ 32 as of 05 May 15:30 . The P/E Ratio of Parmax Pharma Ltd changed from 21 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Rekvina Labs Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Parmax Pharma Ltd changed from ₹ 13.28 crore on March 2021 to ₹ 15.8 crore on March 2025 . This represents a CAGR of 3.54% over 5 yearsThe Market Cap of Rekvina Labs Ltd changed from ₹ 2.39 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 5 years The revenue of Parmax Pharma Ltd for the Dec '25 is ₹ 4.33 crore as compare to the Sep '25 revenue of ₹ 2.54 crore. This represent the growth of 70.47% The revenue of Rekvina Labs Ltd for the Dec '25 is ₹ 0.35 crore as compare to the Sep '25 revenue of ₹ 0.2 crore. This represent the growth of 75% The ebitda of Parmax Pharma Ltd for the Dec '25 is ₹ -0.19 crore as compare to the Sep '25 ebitda of ₹ -1.58 crore. This represent the decline of -87.97% The ebitda of Rekvina Labs Ltd for the Dec '25 is ₹ -0.12 crore as compare to the Sep '25 ebitda of ₹ -0.03 crore. This represent the growth of 300% The net profit of Parmax Pharma Ltd changed from ₹ 0.01 crore to ₹ -0.73 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Rekvina Labs Ltd changed from ₹ -0.07 crore to ₹ -0.12 crore over 6 quarters. This represents a CAGR of 43.24% The Dividend Payout of Parmax Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Rekvina Labs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Parmax Pharma Ltd

Incorporated in Nov.'94, Parmax Pharma Ltd (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara.
The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc.
The Company then discontinued their business activities for few years due to various reasons.
Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA.

About Rekvina Labs Ltd

Rekvina Labs Limited was incorporated on 1st November 1988.
From a small domestic company at inception in middle of 80's, Rekvina has grown formidably to be an integrated, Indian pharmaceutical company with sales in excess of Rs 20 Crore.
It is registered in England and Wales as a Public Limited Company.
The Company is a Quality producer of Pharmaceutical formulations for its customer as per their specific requirements.
It provide contract research and manufacturing services to customers. The Company is mainly engaged in manufacturing and marketing of pharmaceutical products.

FAQs for the comparison of Parmax Pharma Ltd and Rekvina Labs Ltd

Which company has a larger market capitalization, Parmax Pharma Ltd or Rekvina Labs Ltd?

Market cap of Parmax Pharma Ltd is 11 Cr while Market cap of Rekvina Labs Ltd is 25 Cr

What are the key factors driving the stock performance of Parmax Pharma Ltd and Rekvina Labs Ltd?

The stock performance of Parmax Pharma Ltd and Rekvina Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Parmax Pharma Ltd and Rekvina Labs Ltd?

As of May 5, 2026, the Parmax Pharma Ltd stock price is INR ₹32.0. On the other hand, Rekvina Labs Ltd stock price is INR ₹41.6.

How do dividend payouts of Parmax Pharma Ltd and Rekvina Labs Ltd compare?

To compare the dividend payouts of Parmax Pharma Ltd and Rekvina Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.